| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
Verhulst J, Ferdinande L, Demetter P, et al. Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis[J]. J Clin Pathol, 2012, 65(5): 381-388.
|
| [3] |
Hugen N, van Beek JJ, de Wilt JH, et al. Insight into mucinous colorectal carcinoma: clues from etiology[J]. Ann Surg Oncol, 2014, 21(9): 2963-2970.
|
| [4] |
Walsh MD, Clendenning M, Williamson E, et al. Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype[J]. Mod Pathol, 2013, 26(12): 1642-1656.
|
| [5] |
Hugen N, Simons M, Halilovic A, et al. The molecular background of mucinous carcinoma beyond MUC2[J]. J Pathol Clin Res, 2015, 1(1): 3-17.
|
| [6] |
Sicard JF, Le Bihan G, Vogeleer P, et al. Interactions of intestinal bacteria with components of the intestinal mucus[J]. Front Cell Infect Microbiol, 2017, 7: 387.
|
| [7] |
Li S, Peppelenbosch MP, Smits R. Bacterial biofilms as a potential contributor to mucinous colorectal cancer formation[J]. Biochim Biophys Acta Rev Cancer, 2019, 1872(1): 74-79.
|
| [8] |
Numata M, Shiozawa M, Watanabe T, et al. The clinicopathological features of colorectal mucinous adenocarcinoma and a therapeutic strategy for the disease[J]. World J Surg Oncol, 2012, 10: 109.
|
| [9] |
Hugen N, Brown G, Glynne-Jones R, et al. Advances in the care of patients with mucinous colorectal cancer[J]. Nat Rev Clin Oncol, 2016, 13(6): 361-369.
|
| [10] |
McCawley N, Clancy C, O'Neill BD, et al. Mucinous rectal adenocarcinoma is associated with a poor response to neoadjuvant chemoradiotherapy: A systematic review and meta-analysis[J]. Dis Colon Rectum, 2016, 59(12): 1200-1208.
|
| [11] |
Xiao S, Huang J, Zhang Y, et al. Endoscopy biopsy is not efficiency enough for diagnosis of mucinous colorectal adenocarcinoma[J]. Discov Oncol, 2021, 12(1): 44.
|
| [12] |
Li ZH, You DY, Gao DP, et al. Role of CT scan in differentiating the type of colorectal cancer[J]. Onco Targets Ther, 2017, 10: 2297-2303.
|
| [13] |
Yu MH, Kim YJ, Park HS, et al. Imaging patterns of intratumoral calcification in the abdominopelvic cavity[J]. Korean J Radiol, 2017, 18(2): 323-335.
|
| [14] |
Argiles G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(10): 1291-1305.
|
| [15] |
Hosseini S, Nguyen N, Mohammadianpanah M, et al. Predictive significance of mucinous histology on pathologic complete response rate following capecitabine-based neoadjuvant chemoradiation in rectal cancer: a comparative study[J]. J Gastrointest Cancer, 2019, 50(4): 716-722.
|
| [16] |
Reggiani Bonetti L, Lionti S, Domati F, et al. Do pathological variables have prognostic significance in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and surgery?[J]. World J Gastroenterol, 2017, 23(8): 1412-1423.
|
| [17] |
Reynolds IS, Furney SJ, Kay EW, et al. Meta-analysis of the molecular associations of mucinous colorectal cancer[J]. Br J Surg, 2019, 106(6): 682-691.
|
| [18] |
Luo C, Cen S, Ding G, et al. Mucinous colorectal adenocarcinoma: clinical pathology and treatment options[J]. Cancer Commun (Lond), 2019, 39(1): 13.
|
| [19] |
Reynolds IS, O'Connell E, Fichtner M, et al. Mucinous adenocarcinoma is a pharmacogenomically distinct subtype of colorectal cancer[J]. Pharmacogenomics J, 2020, 20(3): 524-532.
|
| [20] |
Stylianopoulos T, Jain RK. Combining two strategies to improve perfusion and drug delivery in solid tumors[J]. Proc Natl Acad Sci USA, 2013, 110(46): 18632-18637.
|
| [21] |
O'Connell E, Reynolds IS, McNamara DA, et al. Resistance to cell death in mucinous colorectal cancer-a review[J]. Cancers (Basel), 2021, 13(6): 1389.
|
| [22] |
Foxtrot Collaborative G. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial[J]. Lancet Oncol, 2012, 13(11): 1152-1160.
|
| [23] |
Weitz JI, Bauersachs R, Becker B, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial[J]. JAMA, 2020, 323(2): 130-139.
|
| [24] |
Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers[J]. Nat Med, 2020, 26(4): 566-576.
|
| [25] |
Llosa NJ, Luber B, Siegel N, et al. Immunopathologic stratification of colorectal cancer for checkpoint blockade immunotherapy[J]. Cancer Immunol Res, 2019, 7(10): 1574-1579.
|
| [26] |
Benson AB, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: colon cancer, version 2.2018[J]. J Natl Compr Canc Netw, 2018, 16(4): 359-369.
|
| [27] |
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372(26): 2509-2520.
|
| [28] |
Corcoran RB, Atreya CE, Falchook GS, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-Mutant colorectal cancer[J]. J Clin Oncol, 2015, 33(34): 4023-4031.
|